Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 22

1.

[High sensitivity T troponin and CA-125 as prognostic biomarkers in patients with end stage renal disease in hemodialysis].

Moreno JS, Lépori AJ, Novoa P, De Elia R, Guglielmone R, Bono JP.

Rev Fac Cien Med Univ Nac Cordoba. 2016;73(1):8-14. Spanish.

PMID:
27419890
2.

[GESIDA/National AIDS Plan: Consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (Updated January 2015)].

Panel de expertos de GeSIDA y Plan Nacional sobre el Sida.

Enferm Infecc Microbiol Clin. 2015 Oct;33(8):543.e1-43. doi: 10.1016/j.eimc.2015.03.016. Epub 2015 May 7. Spanish.

PMID:
25959461
3.

Why START? Reflections that led to the conduct of this large long-term strategic HIV trial.

INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group, Lundgren J, Babiker A, Gordin F, Emery S, Fätkenheuer G, Molina JM, Wood R, Neaton JD.

HIV Med. 2015 Apr;16 Suppl 1:1-9. doi: 10.1111/hiv.12227. No abstract available.

4.

Etravirine-based antiretroviral therapy in HIV/hepatitis C virus coinfected advanced fibrosis patients receiving triple therapy against hepatitis C virus with telaprevir.

Ramirez ML, Vargas FX, González-Garcia J, Quereda C, Pérez-Elías MJ, de Cea AM, Barros C, Condés E, Moreno JS, Santos I, Torralba M, Aldamiz-Echevarria T, Moreno A.

AIDS. 2014 Oct 23;28(16):2487-9. doi: 10.1097/QAD.0000000000000425. No abstract available.

PMID:
25265233
5.

Outcomes of influenza A(H1N1)pdm09 virus infection: results from two international cohort studies.

Lynfield R, Davey R, Dwyer DE, Losso MH, Wentworth D, Cozzi-Lepri A, Herman-Lamin K, Cholewinska G, David D, Kuetter S, Ternesgen Z, Uyeki TM, Lane HC, Lundgren J, Neaton JD; INSIGHT Influenza Study Group.

PLoS One. 2014 Jul 8;9(7):e101785. doi: 10.1371/journal.pone.0101785. eCollection 2014.

6.

Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation.

Nordell AD, McKenna M, Borges ÁH, Duprez D, Neuhaus J, Neaton JD; INSIGHT SMART, ESPRIT Study Groups; SILCAAT Scientific Committee.

J Am Heart Assoc. 2014 May 28;3(3):e000844. doi: 10.1161/JAHA.114.000844.

7.

Factors associated with D-dimer levels in HIV-infected individuals.

Borges AH, O'Connor JL, Phillips AN, Baker JV, Vjecha MJ, Losso MH, Klinker H, Lopardo G, Williams I, Lundgren JD; INSIGHT SMART Study Group; ESPRIT Study Group; SILCAAT Scientific Committee.

PLoS One. 2014 Mar 13;9(3):e90978. doi: 10.1371/journal.pone.0090978. eCollection 2014.

8.

Fractional modeling of the AC large-signal frequency response in magnetoresistive current sensors.

Ravelo Arias SI, Ramírez Muñoz D, Moreno JS, Cardoso S, Ferreira R, de Freitas PJ.

Sensors (Basel). 2013 Dec 17;13(12):17516-33. doi: 10.3390/s131217516.

9.

The association between serum biomarkers and disease outcome in influenza A(H1N1)pdm09 virus infection: results of two international observational cohort studies.

Davey RT Jr, Lynfield R, Dwyer DE, Losso MH, Cozzi-Lepri A, Wentworth D, Lane HC, Dewar R, Rupert A, Metcalf JA, Pett SL, Uyeki TM, Bruguera JM, Angus B, Cummins N, Lundgren J, Neaton JD; INSIGHT FLU 002 & 003 Study Groups.

PLoS One. 2013;8(2):e57121. doi: 10.1371/journal.pone.0057121. Epub 2013 Feb 27.

10.

Biomarkers and bacterial pneumonia risk in patients with treated HIV infection: a case-control study.

Bjerk SM, Baker JV, Emery S, Neuhaus J, Angus B, Gordin FM, Pett SL, Stephan C, Kunisaki KM; INSIGHT SMART Study Group.

PLoS One. 2013;8(2):e56249. doi: 10.1371/journal.pone.0056249. Epub 2013 Feb 15.

11.

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.

Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, Bloch M, Podzamczer D, Pokrovsky V, Pulido F, Almond S, Margolis D, Brennan C, Min S; SPRING-2 Study Group.

Lancet. 2013 Mar 2;381(9868):735-43. doi: 10.1016/S0140-6736(12)61853-4. Epub 2013 Jan 8.

PMID:
23306000
12.

Polysaccharides immobilized in polypyrrole matrices are able to induce osteogenic differentiation in mouse mesenchymal stem cells.

Moreno JS, Sabbieti MG, Agas D, Marchetti L, Panero S.

J Tissue Eng Regen Med. 2014 Dec;8(12):989-99. doi: 10.1002/term.1601. Epub 2012 Sep 21.

PMID:
22997058
13.

The International Classification of Functioning, Disability and Health: development of capacity and performance scales.

Almansa J, Ayuso-Mateos JL, Garin O, Chatterji S, Kostanjsek N, Alonso J, Valderas JM, Cieza A, Raggi A, Svestkova O, Burger H, Racca V, Vieta E, Leonardi M, Ferrer M; MHADIE Consortium.

J Clin Epidemiol. 2011 Dec;64(12):1400-11. doi: 10.1016/j.jclinepi.2011.03.005. Epub 2011 Jun 12.

PMID:
21669511
14.

Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT).

Pett SL, Carey C, Lin E, Wentworth D, Lazovski J, Miró JM, Gordin F, Angus B, Rodriguez-Barradas M, Rubio R, Tambussi G, Cooper DA, Emery S; INSIGHT-ESPRIT Study Group.

HIV Med. 2011 Apr;12(4):219-27. doi: 10.1111/j.1468-1293.2010.00875.x. Epub 2010 Aug 31.

15.

Use of simple noninvasive biomarkers to predict liver fibrosis in HIV/HCV coinfection in routine clinical practice.

Macías J, González J, Ortega E, Tural C, Cabrero E, Burgos A, Pineda JA; GRAFIHCO Study Team.

HIV Med. 2010 Aug;11(7):439-47. doi: 10.1111/j.1468-1293.2009.00812.x. Epub 2010 Feb 17.

16.

Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection.

Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, Skoutelis A, Goetz MB, Phillips AN; INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study Group.

J Infect Dis. 2009 Sep 15;200(6):973-83. doi: 10.1086/605447.

17.

Interruption of antiretroviral therapy is associated with increased plasma cystatin C.

Mocroft A, Wyatt C, Szczech L, Neuhaus J, El-Sadr W, Tracy R, Kuller L, Shlipak M, Angus B, Klinker H, Ross M; INSIGHT SMART Study Group.

AIDS. 2009 Jan 2;23(1):71-82. doi: 10.1097/QAD.0b013e32831cc129.

18.

Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen.

Fox Z, Phillips A, Cohen C, Neuhaus J, Baxter J, Emery S, Hirschel B, Hullsiek KH, Stephan C, Lundgren J; SMART Study Group.

AIDS. 2008 Nov 12;22(17):2279-89. doi: 10.1097/QAD.0b013e328311d16f.

19.

Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial.

SMART Study Group, El-Sadr WM, Grund B, Neuhaus J, Babiker A, Cohen CJ, Darbyshire J, Emery S, Lundgren JD, Phillips A, Neaton JD.

Ann Intern Med. 2008 Sep 2;149(5):289-99.

PMID:
18765698
20.

Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up.

Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Lundgren JD, Babiker A, El-Sadr W, Emery S, Grund B, Neaton JD, Neuhaus J, Phillips AN.

J Infect Dis. 2008 Apr 15;197(8):1145-55. doi: 10.1086/529523.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk